JP2820796B2 - 生物療法性細胞被覆微小球状体 - Google Patents
生物療法性細胞被覆微小球状体Info
- Publication number
- JP2820796B2 JP2820796B2 JP5519724A JP51972493A JP2820796B2 JP 2820796 B2 JP2820796 B2 JP 2820796B2 JP 5519724 A JP5519724 A JP 5519724A JP 51972493 A JP51972493 A JP 51972493A JP 2820796 B2 JP2820796 B2 JP 2820796B2
- Authority
- JP
- Japan
- Prior art keywords
- microspheres
- skin
- cells
- replacement composition
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000004005 microsphere Substances 0.000 title claims abstract description 157
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 56
- 239000000463 material Substances 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 32
- 239000002002 slurry Substances 0.000 claims abstract description 27
- 238000001727 in vivo Methods 0.000 claims abstract description 17
- 208000028990 Skin injury Diseases 0.000 claims abstract description 8
- 210000004027 cell Anatomy 0.000 claims description 156
- 210000003491 skin Anatomy 0.000 claims description 66
- 210000002950 fibroblast Anatomy 0.000 claims description 64
- 230000002500 effect on skin Effects 0.000 claims description 56
- 210000002510 keratinocyte Anatomy 0.000 claims description 35
- 239000002609 medium Substances 0.000 claims description 25
- 210000004927 skin cell Anatomy 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 206010040882 skin lesion Diseases 0.000 claims description 14
- 231100000444 skin lesion Toxicity 0.000 claims description 14
- 229920000331 Polyhydroxybutyrate Polymers 0.000 claims description 13
- 239000005015 poly(hydroxybutyrate) Substances 0.000 claims description 13
- 229920000218 poly(hydroxyvalerate) Polymers 0.000 claims description 13
- 230000037380 skin damage Effects 0.000 claims description 13
- 238000000576 coating method Methods 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 150000003904 phospholipids Chemical class 0.000 claims description 8
- 239000000654 additive Substances 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 208000014674 injury Diseases 0.000 claims description 5
- 210000002752 melanocyte Anatomy 0.000 claims description 5
- 229920000642 polymer Polymers 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 5
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 3
- 102000006747 Transforming Growth Factor alpha Human genes 0.000 claims description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 229920000728 polyester Polymers 0.000 claims description 3
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- 102000004882 Lipase Human genes 0.000 claims description 2
- 108090001060 Lipase Proteins 0.000 claims description 2
- 239000004367 Lipase Substances 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000019421 lipase Nutrition 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920000768 polyamine Polymers 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 230000003902 lesion Effects 0.000 claims 4
- 230000000996 additive effect Effects 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 229940009098 aspartate Drugs 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 239000000049 pigment Substances 0.000 claims 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 206010052428 Wound Diseases 0.000 abstract description 51
- 239000007943 implant Substances 0.000 abstract description 16
- 238000011282 treatment Methods 0.000 abstract description 10
- 239000002674 ointment Substances 0.000 abstract description 4
- 210000001519 tissue Anatomy 0.000 description 41
- 210000002615 epidermis Anatomy 0.000 description 23
- 210000004207 dermis Anatomy 0.000 description 18
- 239000011159 matrix material Substances 0.000 description 15
- 238000011081 inoculation Methods 0.000 description 13
- 239000007789 gas Substances 0.000 description 10
- 210000001339 epidermal cell Anatomy 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 230000003068 static effect Effects 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 210000003953 foreskin Anatomy 0.000 description 7
- 239000003102 growth factor Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 238000002513 implantation Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 231100000241 scar Toxicity 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 238000011109 contamination Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 230000035699 permeability Effects 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000032544 Cicatrix Diseases 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000009429 distress Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 108010037896 heparin-binding hemagglutinin Proteins 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 238000010899 nucleation Methods 0.000 description 3
- 230000003076 paracrine Effects 0.000 description 3
- 235000015927 pasta Nutrition 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000037387 scars Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 150000003410 sphingosines Chemical class 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012136 culture method Methods 0.000 description 2
- 239000007933 dermal patch Substances 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000001821 langerhans cell Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 235000019766 L-Lysine Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003409 anti-rejection Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000002599 biostatic effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012595 freezing medium Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 244000005714 skin microbiome Species 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000005944 tissue migration Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/985—Skin or skin outgrowth, e.g. hair, nails
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/60—Materials for use in artificial skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
- C12N5/0698—Skin equivalents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2531/00—Microcarriers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Medicinal Preparation (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9210574.1 | 1992-05-18 | ||
| GB929210574A GB9210574D0 (en) | 1992-05-18 | 1992-05-18 | Biotherapeutic cell-coated microspheres for wound/burn and prothesis implant applications |
| PCT/CA1993/000187 WO1993023088A1 (en) | 1992-05-18 | 1993-04-23 | Biotherapeutic cell-coated microspheres |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH07507063A JPH07507063A (ja) | 1995-08-03 |
| JP2820796B2 true JP2820796B2 (ja) | 1998-11-05 |
Family
ID=10715656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5519724A Expired - Fee Related JP2820796B2 (ja) | 1992-05-18 | 1993-04-23 | 生物療法性細胞被覆微小球状体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US5830507A (enExample) |
| EP (1) | EP0641223B1 (enExample) |
| JP (1) | JP2820796B2 (enExample) |
| KR (1) | KR950701533A (enExample) |
| AT (1) | ATE203916T1 (enExample) |
| BR (1) | BR9306375A (enExample) |
| CA (1) | CA2135999C (enExample) |
| DE (1) | DE69330562T2 (enExample) |
| DK (1) | DK0641223T3 (enExample) |
| ES (1) | ES2161229T3 (enExample) |
| GB (1) | GB9210574D0 (enExample) |
| GR (1) | GR3036741T3 (enExample) |
| NZ (1) | NZ252661A (enExample) |
| PT (1) | PT641223E (enExample) |
| RU (1) | RU2104039C1 (enExample) |
| WO (1) | WO1993023088A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654267A (en) * | 1988-12-20 | 1997-08-05 | La Jolla Cancer Research Center | Cooperative combinations of ligands contained within a matrix |
| IL115728A0 (en) * | 1994-10-25 | 1996-01-19 | Boehringer Mannheim Gmbh | Biomaterial containing epithelial cells and use thereof as a transplant |
| IL118376A0 (en) * | 1996-05-22 | 1996-09-12 | Univ Ben Gurion | Polysaccharide sponges for cell culture and transplantation |
| US5972332A (en) * | 1997-04-16 | 1999-10-26 | The Regents Of The University Of Michigan | Wound treatment with keratinocytes on a solid support enclosed in a porous material |
| US20020037566A1 (en) * | 1997-04-16 | 2002-03-28 | Rees Riley S. | Cell-coated supports |
| US5861149A (en) * | 1997-06-04 | 1999-01-19 | Polyheal Ltd. | Methods for wound treatment |
| AU1664299A (en) * | 1997-10-25 | 1999-05-17 | Roche Diagnostics Gmbh | Autodegradable microcarriers and their use |
| CA2321829C (en) * | 1998-03-07 | 2003-05-27 | Daewoong Pharmaceutical Co., Ltd. | Topical composition containing human epidermal growth factor |
| US6378527B1 (en) * | 1998-04-08 | 2002-04-30 | Chondros, Inc. | Cell-culture and polymer constructs |
| PT1071747E (pt) * | 1998-04-17 | 2004-12-31 | Nestle Sa | Linhas celulares imortalizadas derivadas de tecidos cutaneos humanos normais |
| MXPA00010110A (es) * | 1998-04-17 | 2002-08-06 | Angiogenix Inc | Factores angiogenicos terapeuticos y metodos para su uso. |
| ES2435847T3 (es) * | 1998-10-23 | 2013-12-23 | Polyheal Ltd. | Composiciones de microesferas para curar heridas |
| RU2195889C2 (ru) * | 1999-05-24 | 2003-01-10 | Парамонов Борис Алексеевич | Способ дермабразии |
| DE19937102A1 (de) * | 1999-08-06 | 2001-02-15 | Universitaetsklinikum Freiburg | Gewebeersatz und Verfahren zu seiner Herstellung |
| US7056503B2 (en) * | 1999-08-19 | 2006-06-06 | Regents Of The University Of Michigan | Enclosures housing cell-coated supports for treating tumors |
| DE19949290A1 (de) * | 1999-10-12 | 2001-04-26 | Albrecht Bettermann | Partikuläres Konstrukt zur Verwendung in der Transplantationsmedizin |
| RU2184491C2 (ru) * | 2000-03-10 | 2002-07-10 | Озерская Ольга Сергеевна | Способ устранения косметических дефектов кожного покрова |
| KR20010110945A (ko) | 2000-06-09 | 2001-12-15 | 김정용 | 음경 확대 방법 |
| RU2184492C2 (ru) * | 2000-06-13 | 2002-07-10 | Озерская Ольга Сергеевна | Способ дерматохирургического лечения гипотрофических рубцов |
| US6719970B1 (en) * | 2000-07-10 | 2004-04-13 | Alkermes Controlled Therapeutics, Inc. | Method of generating cartilage |
| US20030148924A1 (en) * | 2002-07-09 | 2003-08-07 | Tamar Tennenbaum | Methods and pharmaceutical compositions of healing wounds |
| US20060258562A1 (en) * | 2000-07-31 | 2006-11-16 | Healor Ltd. | Methods and pharmaceutical compositions for healing wounds |
| US20040037828A1 (en) * | 2002-07-09 | 2004-02-26 | Bar-Ilan University | Methods and pharmaceutical compositions for healing wounds |
| US20100129332A1 (en) * | 2000-07-31 | 2010-05-27 | Tamar Tennenbaum | Methods and pharmaceutical compositions for healing wounds |
| JP2002281964A (ja) * | 2000-12-26 | 2002-10-02 | Sanyo Chem Ind Ltd | 細胞生産方法 |
| AUPR289601A0 (en) * | 2001-02-05 | 2001-03-01 | Commonwealth Scientific And Industrial Research Organisation | Method of tissue repair |
| RU2223790C2 (ru) * | 2001-10-25 | 2004-02-20 | ГФУН "Российский научно-исследовательский институт травматологии и ортопедии им. Р.Р. Вредена" | Способ стерилизации биологических трансплантатов окисью этилена в жидкой среде |
| FR2839260B1 (fr) * | 2002-05-03 | 2005-02-25 | Inst Nat Sante Rech Med | Microparticules a base d'un materiau bicompatible et biodegradable, supportant des cellules et des substances biologiquement actives |
| US20050129776A1 (en) | 2002-05-03 | 2005-06-16 | Inserm | Microparticles supporting cells and active substances |
| US7402323B2 (en) * | 2002-08-21 | 2008-07-22 | Akpharma, Inc. | Compositions and methods for treating skin conditions |
| RU2210389C1 (ru) * | 2002-09-10 | 2003-08-20 | Общество с ограниченной ответственностью "Мединтер Плюс" | Спасательное покрывало |
| EP1635782A1 (de) * | 2003-05-24 | 2006-03-22 | JUVENA (International) AG | Gewebekulturmedien als bestandteil von kosmetika |
| WO2005001073A1 (de) * | 2003-06-23 | 2005-01-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Verfahren zur differenzierung von stammzellen in zellen, die ein pankreatisches hormon produzieren |
| NZ545318A (en) * | 2003-07-15 | 2009-06-26 | Univ Bar Ilan | Pharmaceutical compositions for healing wounds comprising insulin and PKC alpha inhibitor |
| ZA200601089B (en) | 2003-08-07 | 2007-05-30 | Hearlor Ltd | Pharmaceutical compositions and methods for accelerating wound healing |
| RU2240809C1 (ru) * | 2003-08-26 | 2004-11-27 | Государственное учреждение "Нижегородский научно-исследовательский институт травматологии и ортопедии" | Способ получения бесклеточного дермального матрикса |
| WO2005037984A1 (ja) * | 2003-10-20 | 2005-04-28 | Jms Co., Ltd. | 細胞取扱装置、組織再生用組成物及び組織再生方法 |
| CA2625674C (en) | 2005-08-29 | 2015-04-14 | Healor Ltd. | Methods and compositions for prevention and treatment of diabetic and aged skin |
| RU2316290C2 (ru) * | 2005-11-21 | 2008-02-10 | Институт биохимии им. А.Н. Баха РАН | Сетчатый эндопротез для восстановительной хирургии |
| WO2008073614A2 (en) * | 2006-11-02 | 2008-06-19 | Akpharma Inc. | Composition and method for enhancing skin cell growth, proliferation and repair |
| KR100805208B1 (ko) | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | 엑센딘 함유 서방성 제제 조성물, 엑센딘 함유 서방성미립구 및 이의 제조 방법 |
| US20100255070A1 (en) * | 2007-05-22 | 2010-10-07 | Prelief Inc. | Compositions and methods for preventing, minimizing and healing skin irritation and trauma |
| EP2653166A3 (en) * | 2007-07-30 | 2014-08-27 | Healor Ltd. | Pharmaceutical composition and related methods |
| WO2009043052A1 (en) * | 2007-09-27 | 2009-04-02 | Columbia University | Methods and systems for forming biocompatible materials |
| WO2009086535A2 (en) * | 2007-12-27 | 2009-07-09 | The Trustees Of Columbia University In The City Of New York | Systems and methods for forming patterned extracellular matrix materials |
| US9095569B2 (en) | 2008-04-18 | 2015-08-04 | Collplant Ltd. | Methods of generating and using procollagen |
| CN102066904B (zh) | 2008-06-13 | 2015-07-15 | 株式会社资生堂 | 皮肤代替膜、模具以及皮肤外用剂的评价方法 |
| EA014044B1 (ru) * | 2008-07-09 | 2010-08-30 | Общество С Ограниченной Ответственностью "Аква-Альянс" | Наносомальная лекарственная форма препарата пролонгированного действия для лечения гепатита с (варианты) |
| US9708416B2 (en) * | 2009-12-04 | 2017-07-18 | Magle Ab | Microspheres of hydrolysed starch with endogenous, charged ligands |
| WO2011083483A2 (en) | 2010-01-11 | 2011-07-14 | Healor Ltd. | Method for treatment of inflammatory disease and disorder |
| JP5241764B2 (ja) * | 2010-03-31 | 2013-07-17 | テルモ株式会社 | 生体適合性材料の評価方法 |
| RU2616866C1 (ru) * | 2015-12-31 | 2017-04-18 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Биорезорбируемый микроноситель для доставки клеток в область заживления и регенерации ран |
| RU2658707C1 (ru) * | 2016-12-28 | 2018-06-22 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ восстановления кожного покрова |
| RU2644633C1 (ru) * | 2016-12-28 | 2018-02-13 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ восстановления кожного покрова |
| CN110960513A (zh) * | 2019-11-29 | 2020-04-07 | 苏州瑞微生物科技有限公司 | 一种微球阵列及其制备方法和用途 |
| CN113201481B (zh) * | 2021-04-19 | 2023-10-13 | 清华大学深圳国际研究生院 | 皮肤微球及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2461002A1 (fr) * | 1979-07-13 | 1981-01-30 | Inst Nat Sante Rech Med | Procede pour stimuler la croissance des cellules d'epiderme humain et produits faisant application dudit procede |
| CA1215922A (en) * | 1984-05-25 | 1986-12-30 | Connaught Laboratories Limited | Microencapsulation of living tissue and cells |
| DE3688168T2 (de) * | 1985-08-14 | 1993-10-28 | Memorial Hospital Cancer | Epidermiszellenextrakte und Verfahren zur Verbesserung der Wundheilung und zur Regenerierung der Epidermis. |
| FR2597499A1 (fr) * | 1986-04-18 | 1987-10-23 | Merieux Inst | Procede de culture microbiologique sur supports de collagene, supports pour ce procede et produits obtenus |
| NZ235556A (en) * | 1986-11-05 | 1991-06-25 | Ethicon Inc | Breast milk substitute containing recombinant human egf |
| US5015584A (en) * | 1987-10-14 | 1991-05-14 | Board Of Regents, The University Of Texas System | Epidermal graft system |
| GB8803697D0 (en) * | 1988-02-17 | 1988-03-16 | Deltanine Research Ltd | Clinical developments using amniotic membrane cells |
| CA1307225C (en) * | 1988-07-19 | 1992-09-08 | David W. Armstrong | Cell culture bioreactor |
| US5135915A (en) * | 1988-10-14 | 1992-08-04 | Genentech, Inc. | Method for the treatment of grafts prior to transplantation using TGF-.beta. |
| JP3073766B2 (ja) * | 1989-04-25 | 2000-08-07 | チルドレンズ メディカル センター コーポレイション | 重合マトリックス上の大容量の細胞の移植方法 |
| US4996154A (en) * | 1989-05-04 | 1991-02-26 | Millipore Corporation | Method for growing cellular tissue |
| US5618531A (en) * | 1990-10-19 | 1997-04-08 | New York University | Method for increasing the viability of cells which are administered to the brain or spinal cord |
-
1992
- 1992-05-18 GB GB929210574A patent/GB9210574D0/en active Pending
-
1993
- 1993-04-23 US US08/338,596 patent/US5830507A/en not_active Expired - Fee Related
- 1993-04-23 AT AT93911706T patent/ATE203916T1/de not_active IP Right Cessation
- 1993-04-23 BR BR9306375A patent/BR9306375A/pt not_active Application Discontinuation
- 1993-04-23 WO PCT/CA1993/000187 patent/WO1993023088A1/en not_active Ceased
- 1993-04-23 JP JP5519724A patent/JP2820796B2/ja not_active Expired - Fee Related
- 1993-04-23 EP EP93911706A patent/EP0641223B1/en not_active Expired - Lifetime
- 1993-04-23 CA CA002135999A patent/CA2135999C/en not_active Expired - Fee Related
- 1993-04-23 RU RU94046192A patent/RU2104039C1/ru not_active IP Right Cessation
- 1993-04-23 PT PT93911706T patent/PT641223E/pt unknown
- 1993-04-23 ES ES93911706T patent/ES2161229T3/es not_active Expired - Lifetime
- 1993-04-23 NZ NZ252661A patent/NZ252661A/en not_active IP Right Cessation
- 1993-04-23 DE DE69330562T patent/DE69330562T2/de not_active Expired - Fee Related
- 1993-04-23 DK DK93911706T patent/DK0641223T3/da active
- 1993-04-23 KR KR1019940704108A patent/KR950701533A/ko active Granted
-
2001
- 2001-09-27 GR GR20010401598T patent/GR3036741T3/el not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| BR9306375A (pt) | 1997-03-04 |
| PT641223E (pt) | 2001-12-28 |
| GB9210574D0 (en) | 1992-07-01 |
| DE69330562T2 (de) | 2002-05-29 |
| ES2161229T3 (es) | 2001-12-01 |
| CA2135999A1 (en) | 1993-11-25 |
| AU668959B2 (en) | 1996-05-23 |
| WO1993023088A1 (en) | 1993-11-25 |
| US5830507A (en) | 1998-11-03 |
| JPH07507063A (ja) | 1995-08-03 |
| KR950701533A (ko) | 1995-04-28 |
| EP0641223B1 (en) | 2001-08-08 |
| CA2135999C (en) | 1999-07-13 |
| RU94046192A (ru) | 1996-10-10 |
| ATE203916T1 (de) | 2001-08-15 |
| DE69330562D1 (de) | 2001-09-13 |
| NZ252661A (en) | 1996-09-25 |
| GR3036741T3 (en) | 2001-12-31 |
| RU2104039C1 (ru) | 1998-02-10 |
| AU4257993A (en) | 1993-12-13 |
| EP0641223A1 (en) | 1995-03-08 |
| KR100381207B1 (enExample) | 2003-10-23 |
| DK0641223T3 (da) | 2001-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2820796B2 (ja) | 生物療法性細胞被覆微小球状体 | |
| US8765468B2 (en) | Surgical device for skin therapy or testing | |
| US20050129730A1 (en) | Tissue composites and uses thereof | |
| JPH05506169A (ja) | 合成生体皮膚等価物 | |
| JPH11503946A (ja) | ヒアルロン酸誘導体を基本とするバイオ適合性物質を支持体として含む人工皮膚 | |
| JP2003047652A (ja) | 結合組織粒子とポリマーからなる糸 | |
| JP2005537845A (ja) | フィブリン細胞支持体およびその使用方法 | |
| EP3326660A1 (en) | A ready to use biodegradable and biocompatible artificial skin substitute and a method of preparation thereof | |
| WO2000016817A1 (en) | Dermal scaffold using neutralized chitosan sponge or neutralized chitosan/collagen mixed sponge | |
| Lafrance et al. | Novel living skin replacement biotherapy approach for wounded skin tissues | |
| WO2001003750A1 (en) | Human naturally secreted extracellular matrix-coated device | |
| US9259445B2 (en) | Integrated implant system (IIS) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure | |
| AU759066B2 (en) | 3D matrix for producing cell transplants | |
| CN101195044A (zh) | 一种组织工程化微粒组织及其制备方法 | |
| Horch et al. | Keratinocyte monolayers on hyaluronic acid membranes as “upside-down” grafts reconstitute full-thickness wounds | |
| US20240400994A1 (en) | Conditioned medium from cells cultured under hypoxic conditions and uses thereof | |
| AU668959C (en) | Biotherapeutic cell-coated microspheres | |
| WO2007141028A2 (en) | Integrated implant system (iis) biocompatible, biodegradable and bioactive, comprising a biocompatible sterile porous polymeric matrix and a gel, integrating in situ the tridimensional matrix structure | |
| CN1737129B (zh) | 人工皮肤移植物及其制备方法 | |
| HK1156073B (en) | A method of producing a cultured skin device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |